Lexaria Bioscience Corp. LXRP Archives - Page 27 of 27

MondayJul 31, 2017 2:38 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Technology Set to Benefit as Study Shows More Benefits of Cannabidiol

Cannabidiol (CBD) combats anxiety, inflammation, nausea and vomiting Low side-effect profile means high doses of cannabidiol can be used for treatment of schizophrenia, dementia, diabetes and nausea Lower doses promote and maintain health with anti-oxidative, anti-inflammatory and neuroprotective effects Lexaria Bioscience Corp. set to benefit from increasing interest in CBD as patented technology improves taste, rapidity and effectiveness of bioactive compounds including cannabinoids A new scientific review of the safety and side effects of cannabidiol confirms and expands on the myriad known health benefits of cannabidiol and the compound’s lack of side effects. The review, titled “An Update on Safety…

FridayJul 28, 2017 12:17 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (LXRP) Well-Positioned for Growth as First Mover in Canada’s Cannabinoid Market

Among players in Canada’s emerging cannabinoid market, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth. Lexaria is a revenue-generating company engaged in developing and out-licensing proprietary technology for delivering bioactive compounds, including cannabinoids, and the company’s products utilize this patented lipophilic technology, which has been proven to enhance the bioavailability of orally ingested cannabinoids and also improve their taste. “With full legalization expected in 2018, the Canadian market for cannabis extracts and oils is expected to top C$1.6 billion by 2020. Lexaria is at the forefront of innovation in the biosciences sector as pioneering biopharmaceutical companies in…

TuesdayJul 25, 2017 3:49 pm

Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) Patented Cannabinoid Delivery System Approved

Patented lipophilic delivery system increases bio-absorption Patents cover broad range of lipophilic bio-actives, including cannabinoids, vitamins, other pharma 19 patents filed across 44 countries First international patent issued and approved in Australia Any argument over the efficacy of medicinal marijuana is settled science. Recent prestigious clinical studies have provided conclusive evidence that medical cannabinoids are effective medicine for a variety of diseases and ailments (http://dtn.fm/C9Sao). However, the human gastrointestinal tract just doesn’t absorb cannabinoids effectively, and much of what is ingested is simply excreted by the body. Subsequently, onset times and effectiveness vary wildly. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB:…

ThursdayJul 20, 2017 9:07 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Commences Lab Work with National Research Council of Canada

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced the start of laboratory work under its collaborative research project with the National Research Council of Canada (“NRC”). “We are delighted to have commenced formulation development and characterization work together with the NRC,” John Docherty, president of Lexaria Bioscience, stated in the news release. “The NRC team has extensive knowledge and experience in the field of lipid based delivery systems relating to pharmaceutical products, natural health products and functional foods. This collaboration will significantly assist Lexaria in further developing and characterizing its IP portfolio.” Moving forward, several studies will be…

TuesdayJul 18, 2017 2:39 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Well-positioned For Expanding Canadian Cannabinoid Market

Lexaria Bioscience Corp. well-positioned for growth in expanding Canadian cannabinoid market Canadian market for cannabis extracts and oils expected to top C$1.6 billion by 2020 Company’s patented technology infuses organically sourced hemp oil into molecules of other substances such as lipids, the basis of the human endocannabinoid system Patented technology enables better-tasting hemp oil-infused gourmet food products with improved bioavailability of cannabinoids Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is well-positioned for growth in the emerging Canadian cannabinoid market. Lexaria is an innovative revenue-generating company developing and out-licensing proprietary technology for delivering bioactive compounds including cannabinoids. With full legalization expected…

TuesdayJul 18, 2017 9:01 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Awarded Australian Patent Protecting Cannabis Infused Edibles

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that the Australian Patent Office has granted patent #2015274698, which protects Lexaria’s method of improving absorption, speed of onset and taste of cannabinoid active agents in edible products. The term of the patent is 20 years from June 10, 2015. “We are very pleased to have received this patent which effectively covers all cannabis oil extract formulated edibles utilizing our technology in Australia,” Chris Bunka, CEO of Lexaria, stated in the news release. “This patent award allows us to confidently enter the recently legalized Australian cannabis marketplace where we will…

WednesdayJul 12, 2017 12:49 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is “One to Watch”

Revenue-generating biosciences company focused on improving the delivery of bioactive compounds through gourmet foods Proprietary technology shown to enhance the bioavailability of orally ingested cannabinoids while improving the taste Actively developing and selling hemp oil-based gourmet food products through consumer brands ViPova™ and Lexaria Energy Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP